臨床外科69巻1号

2014年01月発行

特集 見直される膵癌診療の新展開 治療における新展開―切除不能例への治療戦略

切除不能膵癌に対する抗がん＋分子標的薬治療

著者： 古瀬純司¹ 岡野尚弘¹ 成毛大輔¹ 春日章良¹ 北村浩¹ 高須充子¹ 長島文夫¹

所属機関： ¹杏林大学医学部内科学腫瘍内科

ページ範囲：P.58 - P.63

【ポイント】

◆切除不能例に対する標準治療として，GEM単独，S-1単独，GEM＋エルロチニブ併用療法が推奨されている．

◆海外において転移例に対し，FOLFIRINOX療法あるいはGEM＋ナブパクリタキセル併用療法の有用性が報告された．わが国でも第Ⅱ相試験が行われており，今後保険適用の承認が見込まれている．

◆切除不能例に対する化学療法では多くのGEM-based併用療法として分子標的薬の開発が行われているが，ほとんど結果が残せていない．現在までGEM＋エルロチニブ併用療法がGEM単独を上回る成績を示しているのみである．

参考文献

1）Burris HA 3rd, Moore MJ, Andersen J, et al：Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer：a randomized trial. J Clin Oncol 15：2403-2413, 1997

2）Okada S, Ueno H, Okusaka T, et al：Phase I trial of gemcitabine in patients with advanced pancreatic cancer. Jpn J Clin Oncol 31：7-12, 2001

3）Ueno H, Ioka T, Ikeda M, et al：Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan：GEST study. J Clin Oncol 31：1640-1648, 2013

4）Moore MJ, Goldstein D, Hamm J, et al：Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25：1960-1966, 2007

5）Okusaka T, Furuse J, Funakoshi A, et al：Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102：425-431, 2011

6）Conroy T, Desseigne F, Ychou M, et al：FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364：1817-1825, 2011

7）Von Hoff D, Ervin TJ, Arena FP, et al：Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med, 2013 ［Epub ahead of print］

8）Bramhall SR, Schulz J, Nemunaitis J, et al：A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87：161-167, 2002

9）Van Cutsem E, van de Velde H, Karasek P, et al：Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22：1430-1438, 2004

10）Philip PA, Benedetti J, Corless CL, et al：Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma：Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28：3605-3610, 2010

11）Kindler HL, Niedzwiecki D, Hollis D, et al：Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer：phase III trial of the Cancer and Leukemia Group B（CALGB 80303）. J Clin Oncol 28：3617-3622, 2010

12）Van Cutsem E, Vervenne WL, Bennouna J, et al：Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27：2231-2237, 2009

13）Kindler HL, Ioka T, Richel DJ, et al：Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma：a double-blind randomised phase 3 study. Lancet Oncol 12：256-262, 2011

14）Rougier P, Riess H, Manges R, et al：Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer 49：2633-2642, 2013

15）Gonçalves A, Gilabert M, François E, et al：BAYPAN study：a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 23：2799-2805, 2012

16）da Cunha Santos G, Dhani N, Tu D, et al：Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer：National Cancer Institute of Canada Clinical Trials Group Study PA. 3. Cancer 116：5599-5607, 2010

17）Itakura J, Ishiwata T, Friess H, et al：Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3：1309-1316, 1997

18）Reni M, Cereda S, Milella M, et al：Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma：A phase II randomised trial. Eur J Cancer, 2013［Epub ahead of print］

19）Strumberg D, Schultheis B, Ebert MP, et al：Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients（pts）with advanced pancreatic cancer（PC）. 2013 ASCO Annual Meeting. J Clin Oncol 31 （suppl）：abstr 4009, 2013

20）Infante JR, Somer BG, Park JO, et al：A randomized, double-blind, placebo-controlled trial of trametinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of thepancreas. 2013 Gastrointestinal Cancers Symposium. J Clin Oncol 30（suppl 34）：abstr 291, 2012